India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
India’s economic future is increasingly tied to industries that are still evolving but promise massive…
In an unprecedented and emotionally charged development, Maharashtra witnessed a historic political moment as Sunetra…
A research team reported that they had completely eliminated the most aggressive form of pancreatic…
Rivers have always been an important part of human life, providing water, food, and transportation.…
Elena Rybakina won the Australian Open 2026 women’s singles title after defeating World No. 1…
India’s largest public sector steelmaker has achieved a milestone that goes beyond production and profits.…